From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.
News|Articles|June 2, 2025
Dermatology Month in Review: May 2025
Author(s)HCPLive Editorial Staff
Fact checked by: Tim Smith
This Month in Review summary includes a list of some of the most notable or impactful news in the dermatology field from May 2025.
Advertisement
Advertisement
Every month, the HCPLive editorial team publishes a new iteration of our Month in Review series, during which a summary provides several highlights of the most notable news coverage from the month in each medical subfield. Here, the team spotlights some of the most significant stories in the field of
Related to this article
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Advertisement
Advertisement